Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

INDEPENDENT AUDITORS' REPORT

To,

THE MEMBERS OF MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

Report on Financial Statements

Opinion

We have audited the accompanying financial statements of Medicarenx Multispecialty Hospital Private Limited ("The Company") which comprises the Balance Sheet as at March 31, 2026 the Statement of Profit and Loss & Statement of Cash flows for the year ended March 31, 2026, and a summary of the significant accounting policies and other explanatory information (herein after referred to as 'the Financial Statements').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2026, and its Profit and Loss and it's cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

When we read such other information as and when made available to us and if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance

The draft Board of Director's Report was made available to us and we did not find any material inconsistency in the Report. Hence we have nothing to report in this regard.

Responsibility of Management and Those Charged with Governance (TCWG) for the Financial Statements

The Company's management is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position , financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of the users of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in

(i) Planning the scope of our audit work and in evaluating the results of our work; and
(ii) to evaluate the effect of any identified misstatements in the financial statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. The Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of Section 143(11) of the Companies Act, 2013, is not applicable to the Company. Accordingly, the reporting requirements under paragraphs 3 and 4 of the Order are not applicable, and no Annexure A has been annexed to this report.

2. As requested by Section 143 (3) of the Act, we report that:

   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   (c) The Balance Sheet, the Statement of Profit and Loss, and the cash flow statement dealt with by this Report are in agreement with the books of account.

   (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

KALE MALDE & CO
DOMBIVALI

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

(e) On the basis of the written representations received from the directors as on March 31, 2026, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164 (2) of the Act.

(f) The reporting requirement under Section 143(3)(i) of the Companies Act, 2013 relating to the adequacy of internal financial controls over financial reporting and the operating effectiveness of such controls is not applicable to the Company. Accordingly, our report does not include a separate report on internal financial controls over financial reporting, and Annexure B has not been annexed to this report.

(g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.

ii. During the year, the company has not entered into any long term contracts including derivative contract, and therefore question of provisioning for material foreseeable does not arises.

iii. (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or

DOMBIVALI
FRN:154422W

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.

(d) Based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility except that the audit trail was not enabled at the database level for accounting software to log any direct data changes. For accounting software for which audit trail feature is enabled, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software and we did not come across any instance of audit trail feature being tampered with during the course of our audit.

iv. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

For KALE MALDE & CO.
Chartered Accountants
Reg No. :0154422W

KALE MALDE & CO. DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

CA. Alpesh Malde
Partner
Membership No. 138034
ICAI UDIN: 26138034THSPXX4619
Place: Dombivli
Date: 28/05/2026

MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED
CIN : U86100MH2025PTC463537
Audited Balance Sheet as at 31st March, 2026

All amounts in Lakhs unless otherwise stated

Particulars	Note	As at March 31, 2026	As at March 31, 2025
I. EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	3	1.00	.00
Reserves and Surplus	4	-.12	.00
		.88	**.00**
Non-current liabilities			
Long-Term Borrowings	5	17.99	.00
		17.99	**.00**
Current liabilities			
Short-Term Borrowings	6	.00	.00
Trade Payables			
total outstanding dues of micro and small	7	.45	.00
total outstanding dues of creditors other than micro	7	7.50	.00
		7.95	**.00**
TOTAL EQUITY AND LIABILITIES		**26.82**	**.00**
II. ASSETS			
Non-current assets			
Property, Plant and Equipment and Intangible Assets			
Capital work-in-progress	8	25.51	.00
Other non-current assets	9	1.02	.00
		26.53	**.00**
Current assets			
Cash and Cash Equivalents	10	.29	.00
		.29	**.00**
TOTAL ASSETS		**26.82**	**.00**

The accompanying notes are an integral part of the Financial Statements
As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 28/05/2026
Place: Dombivli
ICAI UDIN:26138034THSPXX4619

For and on behalf of the Board of Directors of
MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

Jagdish Umakant Nayak
Director
DIN : 00646672
Date: 28/05/2026
Place: Thane

Dhanjay Sunil Vibhandik
Director
DIN : 11439127
Date: 28/05/2026
Place: Thane

MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

CIN : U86100MH2025PTC463537

Audited Statement of Profit And Loss for the year ended 31st March, 2026

All amounts in Lakhs unless otherwise stated

Particulars	Note	Year ended March 31, 2026	Year ended March 31, 2025
INCOME			
Revenue From Operations	11	.33	.00
Total Income		**.33**	**.00**
EXPENSES			
Other Expenses	12	.45	.00
Total Expenses		**.45**	**.00**
Profit before tax		**-.12**	**.00**
TAX EXPENSES			
Current Tax	-	.00	.00
PROFIT FOR THE YEAR		**-.12**	**.00**
EARNINGS PER EQUITY SHARE			
Basic (Face value of Rs.10 each)	13	(0.12)	-
Diluted (Face value of Rs.10 each)	13	(0.12)	-

The accompanying notes are an integral part of the Financial Statements

As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 28/05/2026
Place: Dombivli
ICAI UDIN:26138034THSPXX4619

For and on behalf of the Board of Directors of
MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

Jagdish Umakant Nayak
Director
DIN : 00646672
Date: 28/05/2026
Place: Thane

Dhanjay Sunil Vibhandik
Director **Director**
DIN : 11439127
Date: 28/05/2026
Place: Thane

MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

CIN : U86100MH2025PTC463537

Statement of Cash Flows for the year ended 31st March, 2026

All amounts in Lakhs unless otherwise stated

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	-.12	.00
Adjustments for :		
Interest expense	.00	.00
Operating Profit Before Working Capital Changes	**-.12**	**.00**
Increase / (Decrease) in Trade Payables	7.95	.00
Decrease / (Increase) in Other Non-Current assets	-1.02	.00
Net Cash generated from / (used in) Operating Activities	**6.81**	**.00**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment and Intangible Assets	-25.51	.00
Net Cash generated from / (used in) Investing Activities	**-25.51**	**.00**
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Share capital	1.00	.00
Proceeds from Long-Term Borrowings	17.99	.00
Proceeds from Short-Term Borrowings	.00	.00
Interest paid	.00	.00
Net Cash generated from / (used in) Financing Activities	**18.99**	**.00**
Net Increase / (Decrease) In Cash and Cash Equivalents	**.29**	**.00**
Cash and Cash Equivalents at the Beginning	.00	.00
Cash and Cash Equivalents at the End	**.29**	**.00**

The accompanying notes are an integral part of the Financial Statements

As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 28/05/2026
Place: Dombivli
CAI UDIN:26138034THSPXX4619

For and on behalf of the Board of Directors of
MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

Jagdish Umakant Nayak
Director
DIN : 00646672
Date: 28/05/2026
Place: Thane

Dhanjay Sunil Vibhandik
Director
DIN : 11439127
Date: 28/05/2026
Place: Thane

MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED
CIN : U86100MH2025PTC463537

Note 1 & 2: Notes to the financial statements for the year ended 31st March, 2026

Note 1: Background

MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED (the 'Company') is a Private Limited Company, domiciled in India with its registered office located at 01, 02, 101 & 102, GROUND & FIRST FLOOR, SHRIRAM DARSHAN, OPP JANHVI HALL, BADLAPUR E.D, AMBARNATH, THANE- 421503, Badlapur E.D., Thane, Ambarnath, Maharashtra, India, 421503. The Registration Number of the Company is U86100MH2025PTC463537 incorporated on Decemeber 19, 2025.

Note 2: SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation of financial statements:

The financial statements have been prepared in compliance with Generally Accepted Accounting Principles ('GAAP') in India, under the historical cost convention. GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ("Act") read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in th accounting policy hitherto in use.

2.2 Use of estimates

The preparation of financial statement requires the management of the company to make estimates and assumptions that affect the reported balance of assets and liabilities as at the date of the financial statement and reported amounts of income and expenses during the year.Example of such estimates includes employee benefits, provision for taxes, accounting for the useful lives of depreciable fixed assets etc. The Company has considered internal and external information while finalising various estimates in relation to its financial statements up to the date of the approval by the Board of Directors and has not identified any material impact on the carrying value of assets, liabilities or provisions. Since the situations are continuously evolving, the impact assessed may be different from the estimates made as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the company and take necessary measures to address the situation.

2.3 Revenue Recognition

Revenue is recognized to the extent that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue from clinical diagnostic services is recognized on the completion of the services and is at net of reversal and discounts. Interest and other income are recognized on accrual basis.

2.4 Property Plant and Equipment

Property Plant and Equipment are stated at historical cost less depreciation. Cost also includes all expenses incurred to bring the asset to its present location and condition. Pre-operative expenses not pertaining to any specific fixed assets are allocated proportionately. Depreciation provided on Written Down Value Method ('WDV') is based on the estimated useful lives of the assets as prescribed under Part C of Schedule II of the Companies Act 2013.

2.5 Depreciation/Amortization

Depreciation provided on Written Down Value Method ('WDV') is based on the estimated useful lives of the assets as prescribed under Part C of Schedule II of the Companies Act 2013. For additions and disposals, depreciation is provided pro-rata for the period of use. However, where the useful life of any assest is exhausted on the first day of financial year, same is written off as depreciation in Statement of Profit & Loss.
The useful lives for the Property, Plant & Equipment as presribed under Part C of Schedule II of the Companies Act 2013 is as follows :

Plant and machinery	5-15 years
Office equipment	5 years
Computer equipment and Software	3 years
Furniture and fixtures	10 years
Vehicles	10 years
Intangible Assets	3 years

2.6 Inventories

Inventory is valued at cost or net realizable value whichever is lower. Cost of inventory includes cost of purchase, cost of conversion, other cost incurred to bring the material to its present location and condition.

2.7 Leases

In accordance with Accounting Standard 19 "Accounting for leases", lease arrangements, where the risks and rewards incidental to ownership of an asset substantially vests with the lessor, are recognised as operating leases. Lease payments under operating lease are recognised as an expense in the profit and loss account.

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

2.8 Employee retirement and other benefits

The Company has a gratuity plan, wherein every employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service. The gratuity plan of the Company is an unfunded scheme. The Company has provided liability in the books of accounts based on the acturial valuation performed by independent valuer.

1) Defined Contribution Plans :
Contributions to defined contribution retirement benefit schemes are recognised as an expense in the profit and loss account during the period in which the employee renders the related service. e.g. Provident fund.

2) Defined Benefit Plans :
Gratuity and leave encashment schemes are defined benefits. The present value of the obligation under such defined benefit plans is determined based on actuarial valuation carried out by an independent actuary at the balance sheet date using the Projected Unit Credit Method, which recognises each period of service as giving rise to one additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation.

2.9 Provisions, Contingent Liabilities & Contingent Assets

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. These are reviewed at each balance sheet date and adjusted to reflect the current managment estimates. Contingent Liabilities are discolsed in respect of possible obligations that arise from past events but their existence is confirmed by the occurence or non-occurence of one or more uncertain future events not wholly within the control of the Company. A Contingent Asset is a possible asset that arises from past events but their existence is confirmed by the occurence or non-occurence of one or more uncertain future events not wholly within the control of the entity. Contingent Assets are not recognised till the realization of the income is virtually certain. However the same are disclosed in the financial statements where an inflow of economic benigit is probable.
A Contingent asset neither recognized nor disclosed in the financial statements.

2.10 Taxation

Income tax expense comprises current tax expense, deferred tax expense or credit computed in accordance with the relevant provisions of the Income Tax Act, 1961. Provision for current taxes is recognised under the taxes payable method based on the estimated tax liability computed after taking credit for allowances and exemptions in accordance with the Indian Income tax Act, 1961.

2.11 Defferred tax assets and Liabilities

Deferred tax assets and liabilities are recognised for the future tax consequences attributable to timing differences that result between the profits offered for income taxes and the profits as per the financial statements of the Company. Deferred tax assets and liabilities are measured using the tax rates and the tax laws that have been enacted or substantively enacted by the balance sheet date. The effect on deferred tax assets and liabilities of a change in tax rates is recognised in the period that includes the enactment rate. Deferred tax assets in respect of carry forward losses are recognised only to the extent that there is virtual certainty that sufficient future taxable income will be available against which such deferred tax asset can be realised. Other deferred tax assets are recognised only if there is a reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. Deferred tax assets are reviewed as at each balance sheet date and written down or written-up to reflect the amount that is reasonably / virtually certain (as the case may be) to be realised.

2.12 Earnings Per Share

The basic earnings per share is computed by dividing the net profit attributable to the equity shareholders for the year by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed using the weighted average number of equity shares and also the weighted average number of equity shares that could have been issued on the conversion of all dilutive potential equity shares. The dilutive potential equity shares are adjusted for the proceeds receivable, had the shares been actually issued at fair value. Dilutive potential equity shares are deemed converted as of the beginning of the year, unless they have been issued at a later date.

2.13 Investments
Long-term investments are valued at cost less provision for diminution in value, if the diminution is other than temporary. Current investments are valued at lower of cost and fair value. Gain or loss arising on the sale of investments is computed as a difference between carrying amount and the proceeds from sale, net of any expenses. Such gain or loss is recognised in the Statement of Profit and Loss.

2.14 Trade Receivables and Loans and Advances
Trade Receivables and Loans and Advances are presented after making adequate provision for any shortfall in their recovery. The provision and any subsequent recovery is recognised in the Profit and Loss statement. Bad debts are written off when they are identified.

2.15 Cash and cash equivalents
All highly liquid financial instruments, which are readily convertible into known amount of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase are considered to be cash equivalents.

2.15 Investments
Long-term investments are valued at cost less provision for diminution in value, if the diminution is other than temporary. Current investments are valued at lower of cost and fair value. Gain or loss arising on the sale of investments is computed as a difference between carrying amount and the proceeds from sale, net of any expenses. Such gain or loss is recognised in the Statement of Profit and Loss.

2.16 Trade Receivables and Loans and Advances
Trade Receivables and Loans and Advances are presented after making adequate provision for any shortfall in their recovery. The provision and any subsequent recovery is recognised in the Profit and Loss statement. Bad debts are written off when they are identified.

2.17 Cash and cash equivalents
All highly liquid financial instruments, which are readily convertible into known amount of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase are considered to be cash equivalents.

KALE MALDE & CO
DOMBIVALI
FRN-134422W
CHARTERED ACCOUNTANTS

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

Notes to the Financial Statements

Year ended March 31, 2026 | All amounts in Lakhs unless otherwise stated

3. Share capital

Particulars	As at March 31, 2026	As at March 31, 2025
Authorised		
5,00,000 Equity shares of Rs. 10 each	50.00	.00
Issued, subscribed and fully paid up		
10,000 Equity shares of Rs. 10 each	1.00	.00
Total	**1.00**	**.00**

Reconciliation of the number of Equity Shares outstanding

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of Shares	Amount	No. of Shares	Amount
As at the beginning of the period	-	-		-
Add : Shares issued during the period	10,000	1.00		-
Less : Deductions during the period		.00		-
As at the end of the period	**10,000**	**1.00**	-	-

Rights, preferences and restrictions attached to shares

The Company has issued only one class of equity shares having a par value of Rs. 10 per share. Each equity shareholder is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, in proportion to their shareholding. Any dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.

Equity Shares held by Holding Company and Subsidiary of Holding Company

Name of the Company	As at March 31, 2026		As at March 31, 2025	
	No. of Shares	% Shares	No. of Shares	% Shares
Clinitech laboratory Limited	6,000	60.00%		-
Total	**6,000**	**60.00%**	-	-

Details regarding number and class of shares for the period of five years immediately preceding March 31, 2026

a) The company has not allotted any shares as fully paid-up without payment being received in cash.
b) The company has not alloted any shares as fully paid up bonus shares.
c) The company has not bought back any of its shares.

Other Details regarding issue of shares

There are no shares reserved for issue under options and contracts / commitments for the sale of shares.
There are no securities convertible into equity or preference shares.
There are no calls unpaid on any shares.
There are no forfeited shares.

Equity Shares held by Promoters at the end of the year

Promoter Name	As at March 31, 2026		As at March 31, 2025		% Change during year
	No. of Shares	%	No. of Shares	%	
Dhananjay Vibhandik	2,000	20.00%		-	100%
Pushpraj Palani Swamy	2,000	20.00%		-	100%
Clinitech laboratory Ltd	6,000	60.00%		-	100%
Total	**10,000**	**100.00%**	-	-	

KALE MALDE & CO CHARTERED ACCOUNTANTS DOMBIVALI FRN:154422W

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

. Reserves and Surplus

Particulars	As at March 31, 2026	As at March 31, 2025
Surplus		
Opening Balance	.00	.00
(+) Net Profit or (Loss) for the period	-.12	.00
Closing Balance	-.12	.00
Total	**-.12**	**.00**

. Long-Term Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
Secured		
Term loans from bank	17.99	.00
Total	**17.99**	**.00**

e Company's term loan is secured by an exclusive first charge by way of hypothecation over specified machinery, ectrical installations, furniture and fixtures, office equipment, and other movable fixed assets charged in favour of the nder, in accordance with the terms and conditions of the loan agreement.

. Short-Term Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
Unsecured Loans		
From Related Parties		
Clinitech laboratory Ltd	-	
Others	-	
Total	-	-

Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of micro and small enterprises	.45	.00
Total outstanding dues of other than micro and small enterprises	7.50	.00
Total	**7.95**	**.00**

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

MEDICARENA MULTISPECIALITY HOSPITAL PVT LTD

geing for trade payables from the due date of payment for each of the category as at March 31, 2026

Particulars			Outstanding for following periods from due date of payment				
	Unbilled	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
MSME	.00	.00	.45	.00	.00	.00	.45
Others	.00	.00	7.50	.00	.00	.00	7.50
Disputed dues – MSME	.00	.00	.00	.00	.00	.00	.00
Disputed dues – Others	.00	.00	.00	.00	.00	.00	.00
Total	**.00**	**.00**	**7.95**	**.00**	**.00**	**.00**	**7.95**

geing for trade payables from the due date of payment for each of the category as at March 31, 2025

Particulars			Outstanding for following periods from due date of payment				
	Unbilled	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
MSME							-
Others							-
Disputed dues – MSME							-
Disputed dues – Others							-
Total	-	-	-	-	-	-	-

utstanding is drawn based on the invoice date. The above amounts excludes retention amounts

ues to Micro and Small Enterprises as aforesaid have been determined to the extent such parties have been identified on e basis of information collected by the Management. Provision for interest is not required in the opinion of management as ere has been no delay and the payments are as per regular business agreements of the entity.

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

MEDICARE MULTISPECIALITY HOSPITAL PVT LTD

All amounts in Lakhs unless otherwise stated

8. Property, Plant and Equipment and Intangible Assets for 'Current period'

Particulars	Gross Block				Depreciation and Amortisation				Net Book Value	
	As at March 31, 2025	Additions	Deductions	As at March 31, 2026	As at March 31, 2025	For the year	On Deductions	As at March 31, 2026	As at March 31, 2026	As at March 31, 2025
8A. Capital work-in-progress	-	25.51		25.51	.00	.00	.00	.00	25.51	.00

8. Property, Plant and Equipment and Intangible Assets for 'Previous period'

Particulars	Gross Block				Depreciation and Amortisation				Net Book Value	
	As at March 31, 2024	Additions	Deductions	As at March 31, 2025	As at March 31, 2024	For the year	On Deductions	As at March 31, 2025	As at March 31, 2025	As at March 31, 2024
8A. Capital work-in-progress	-	-		-	-	-	-	-	-	-

Ageing schedule for Projects in progress

Particulars	As at March 31, 2026					As at March 31, 2025				
	Less than 1 year	1 -2 years	2 - 3 years	More than 3 years	Total	Less than 1 year	1 -2 years	2 - 3 years	More than 3 years	Total
Capital work-in-progress										
Projects in Progress					-					-
Projects temporarily suspended					-					-

KALE MALDE & CO DOMBIVALI FRN:154122W

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

9. Other non-current assets

Particulars	As at March 31, 2026	As at March 31, 2025
Preliminary Expenditure	1.02	.00
Total	**1.02**	**.00**

10. Cash and Cash Equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Cash on Hand	.29	.00
Balances with Banks	.00	.00
Total	**.29**	**.00**

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

11. Revenue From Operations

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Revenue from operations		
Sale of Services	.33	.00
Total	**.33**	**.00**

12. Other Expenses

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Payment to Auditors	.20	.00
Preliminary expenses W/off	.25	.00
Bank Charges	.00	
Total	**.45**	**.00**

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

13. Earnings Per Share

Particulars	Year ended March 31, 2026	Year ended March 31, 2025
Earnings attributable to equity shareholders (a)	(12,230)	-
Weighted average number of equity shares for calculating basic earning per share (b)	1,00,000	
Basic Earning per share (a/b) in Rs. (Face value of Rs.10 each)	**(0.12)**	-
Earnings attributable to potential equity shares (c)		
Earnings attributable to equity and potential equity shareholders (d=a+c)	(12,230)	-
Weighted average number of potential equity shares (e)		
Weighted average equity shares for calculating diluted earning per share (f=b+e)	1,00,000	-
Diluted Earning per share (d/f) in Rs. (Face value of Rs.10 each)	**(0.12)**	-

14. Related Party Disclosures

List of all Related Parties

Name of Related Party	Relationship
JAGDISH UMAKANT NAYAK	Director
DHANANJAY SUNIL VIBHANDIK	Director
PUSHPARAJ PALANI SWAMY NADAR	Director
CLINITECH LABORATORY LIMITED	Holding Company

Transactions with Related Parties and the status of Outstanding Balances

Name of Related Party	Nature of Relationship	Nature of Transaction or Balance	Year ended March 31, 2026	Year ended March 31, 2025
CLINITECH LABORATORY LIMITED	Holding Company	reimbursement of expenses	1.02	.00
CLINITECH LABORATORY	Holding Company	investment	.60	-

Balance as on March 31, 2026

Name of Related Party	Nature of Relationship	Nature of Transaction or Balance	Year ended March 31, 2026	Year ended March 31, 2025
CLINITECH LABORATORY LIMITED	Holding Company	Outstanding reimbursement of expenses	1.02	.00

15. Analytical Ratios

Ratio	Numerator	Denominator	Year ended March 31,	Year ended March 31,	% Variance
Current ratio (in times)	Current assets	Current liabilities	0.04	-	100.00%
Debt - Equity ratio (in times)	Long Term Borrowings + Short Term	Equity shareholders' funds	29.16	-	100.00%
Debt Service coverage (in times)	Earnings available for debt service	Total debt service	-1.20	-	-100.00%
Return on equity (in %)	Profit after taxes - Preference Dividend	Average equity shareholders' funds	-106.81%	-	-100.00%
Inventory Turnover (in times)	Revenue from operations	Average inventories	-	-	-
Trade receivables turnover (in times)	Revenue from operations	Average trade receivables	-	-	-
Trade payables turnover (in times)	COGS + Other Expenses - Non Cash Expenditure	Average trade payables	0.16	-	100.00%
Net capital turnover (in times)	Revenue from operations	Average of Current assets - Current liabilities	-0.10	-	-100.00%
Net profit ratio (in %)	Profit after taxes	Revenue from operations	-104.70%	-	-100.00%
Return on capital employed (in %)	Profit before tax + Finance costs	Average capital employed	-1.93%	-	-100.00%
Return on investment (in %)	Income from investments	Time weighted average Investments	-	-	-

DOMBIVALI FRN:154182W
MEDICARENX MULTISPECIALITY HOSPITAL PVT LTD

Earning available for debt service = Profit for the year (before taxes) + Finance costs + Depreciation and Amortisation Expense

Total debt service = Finance costs + Principal Repayments

Capital employed = Shareholders' funds + Long Term Borrowings + Short Term Borrowings + Deferred Tax Liabilities (Net) - Intangible assets - Intangible Assets under development

16. Other Disclosures

Disclosure requirements as notified by MCA pursuant to amended Schedule III:

- The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- The Company does not have any Benami Property under Prohibition of Benami Property Transactions Act, 1988.
- The Company has not been declared a wilful defaulter by any lender who has powers to declare a company as a wilful defaulter.
- The Company has no Scheme of Arrangement approved by the competent authority specified under Section 230 to 237 of the Companies Act, 2013.

Previous Period figures have been re-grouped / re-classified, wherever necessary, to make them comparable with Current Period's classification.

The accompanying notes are an integral part of the Financial Statements
As per our report of even date

For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 28/05/2026
Place: Dombivli
ICAI UDIN:26138034THSPXX4619

For and on behalf of the Board of Directors of
MEDICARENX MULTISPECIALITY HOSPITAL PRIVATE LIMITED

Jagdish Umakant Nayak
Director
DIN : 00646672
Date: 28/05/2026
Place: Thane

Dhanjay Sunil Vibhandik
Director **Director**
DIN : 11439127
Date: 28/05/2026
Place: Thane